CAPRICOR THERAPEUTICS, INC. cotiza a 7.47 USD y tiene una capitalización bursátil de $434M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogene…
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.70 | — | $-0.62 |
| Estimado | $-0.41 | $-0.58 | $-0.58 | $-0.55 |
| Sorpresa | — | -20.7% | — | -12.7% |
| Métrica | CAPR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -34.4% | -40.4% | +6.0% |
| ROA | -29.5% | -32.0% | +2.5% |
| Current Ratio | 9.01 | 2.84 | +6.17 |
| Debt / Equity | — | 0.28 | — |